Cyclo Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYTH research report →
Range $0.95 – $0.95
Price Chart
About the company
Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions. Its flagship therapeutic candidate, Trappsol Cyclo, holds orphan drug status and is presently in Phase III clinical trials targeting Niemann-Pick Type C disease.
- CEO
- N. Scott Fine
- IPO
- 2000
- Employees
- 8
- HQ
- Gainesville, FL, US
Get TickerSpark's AI analysis on CYTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $23.59M
- P/E
- -0.59
- Fwd P/E
- 2.06
- PEG
- -0.01
- P/S
- 21.92
- P/B
- 2.47
- EV/EBITDA
- -0.77
- Div Yield
- 0.00%
- Gross Margin
- 90.85%
- Op Margin
- -1862.69%
- Net Margin
- -1863.36%
- ROE
- -730.48%
- ROIC
- -294.82%
Latest fiscal year · YoY change
- Revenue
- $1.08M-21.8%
- Gross Profit
- $977.95K-20.9%
- Op Income
- $-20,050,057
- Net Income
- $-20,057,302-31.3%
- EPS
- $-1.23+32.0%
- OCF Growth
- -7.1%
- FCF Growth
- -7.0%
- 52W High
- $1.62
- 52W Low
- $0.55
- 50D MA
- $0.80
- 200D MA
- $0.83
- Beta
- -0.57
- RSI (14)
- 48
- Avg Volume
- 1.76M
No earnings-call transcripts are available for CYTH yet.
- Free Float
- 35.2%
- Shares Outstanding
- 32.74M
- Float Shares
- 11.51M
of shares held by institutions
19 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Epiq Capital Group, LLC | 689.45K | ▼ 49.98K |
| Blackrock Inc. | 59.51K | ▲ 22.38K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 27, 25 | CONKLING WILLIAM | other | 27,654 |
| Feb 27, 25 | Wong Vivien | other | 25,140 |
| Feb 27, 25 | Cross Shawn | other | 28,597 |
| Feb 27, 25 | Toig Randall M. | other | 33,311 |
| Feb 27, 25 | STRATTAN CE RICK | other | 30,169 |
| Feb 27, 25 | Ostronic Francis Patrick | other | 70,329 |
| Feb 27, 25 | Sieger Markus | other | 58,138 |
| Feb 27, 25 | SHANAHAN WILLIAM S | other | 25,140 |
| Dec 23, 24 | Rafael Holdings, Inc. | other | 3,968,254 |
| Nov 15, 24 | CONKLING WILLIAM | other | 16,660 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CYTH coverage
Recent articles, reports, and earnings notes.
No research on CYTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYTH report →CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
businesswire.com · Feb 20
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
businesswire.com · Feb 7
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders
prnewswire.com · Dec 20
Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio
globenewswire.com · Nov 21
Cyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 14
Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
prnewswire.com · Aug 23
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cyclo Therapeutics, Inc. - CYTH
prnewswire.com · Aug 22
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of VGR, CYTH
accesswire.com · Aug 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.